Filtered By:
Source: Heart Rhythm
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 406 results found since Jan 2013.
Net clinical benefit of anticoagulant treatments in elderly patients with nonvalvular atrial fibrillation: Experience from the real world
Oral anticoagulation (OAC) is effective in stroke prevention in elderly patients with nonvalvular atrial fibrillation (AF), but older patients are also at higher risk of bleeding.
Source: Heart Rhythm - August 17, 2018 Category: Cardiology Authors: Hilmi Alnsasra, Moti Haim, Adi Berliner Senderey, Orna Reges, Maya Leventer-Roberts, Yoav Arnson, Morton Leibowitz, Moshe Hoshen, Meytal Avgil-Tsadok Source Type: research
Accessory Pulmonary Vein Insertion into the Left Atrial Appendage Revealed During Intended Interventional LAA Occlusion
A 64-year-old male with paroxysmal atrial fibrillation and a recent stroke presented with internal carotid artery re-stenosis after prior angioplasty. Cardiovascular risk factors included arterial hypertension, hyperlipidemia, obesity, positive family history, heart failure, and active smoking. Due to high risk of cerebral ischemia as well as periinterventional bleeding complications, the patient was scheduled for interventional left atrial appendage (LAA) closure prior to carotid artery surgery.
Source: Heart Rhythm - July 30, 2018 Category: Cardiology Authors: Octavian Maniuc, Jonas M üntze, Maria Moritz, Peter Nordbeck Source Type: research
Defibrillation testing and clinical outcomes after implantable cardioverter –defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial
The Shockless IMPLant Evaluation (SIMPLE) trial showed that defibrillation testing (DT) at the time of implantable cardioverter –defibrillator (ICD) implant did not improve shock efficacy or reduce mortality. There are no data regarding the risk of complications, including stroke, among patients with atrial fibrillation (AF) who undergo DT.
Source: Heart Rhythm - July 28, 2018 Category: Cardiology Authors: Stefan Bogdan, Michael Glikson, Stuart J. Connolly, Jia Wang, Stefan H. Hohnloser, Ursula Appl, Jorg Neuzener, Philippe Mabo, Xavier Vinolas, Frederick Gadler, Lieselot van Erven, Josef Kautzner, Brandi Meeks, Janice Pogue, Jeff S. Healey Source Type: research
Defibrillation testing and clinical outcomes after implantable cardioverter defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial
The Shockless IMPLant Evaluation (SIMPLE) showed that defibrillation testing (DT) at the time of implantable cardioverter defibrillator (ICD) implant did not improve shock efficacy or reduce mortality. There are no data regarding the risk of complications, including stroke, among patients with atrial fibrillation (AF) who undergo DT.
Source: Heart Rhythm - July 28, 2018 Category: Cardiology Authors: Stefan Bogdan, Michael Glikson, Stuart J. Connolly, Jia Wang, Stefan H. Hohnloser, Ursula Appl, Jorg Neuzener, Philippe Mabo, Xavier Vinolas, Frederick Gadler, Lieselot van Erven, Josef Kautzner, Brandi Meeks, Janice Pogue, Jeff S. Healey Source Type: research
Seeing is Believing: The Importance of Continuous Monitoring to Unmask the Real-World Atrial Fibrillation Recurrence after Ablation
Atrial fibrillation (AF) is a common arrhythmia encountered in clinical practice that contribute to hemodynamic abnormalities, thromboembolic events and hospitalizations.1 The prevalence of AF is around 1% in the general population, substantially increases with age and is estimated to reach 4% in 2050.2, 3 Compared with patients without AF, patients with AF has an increased risk of dementia (hazard ratio [HR]=1.56), myocardial infarction (HR=1.62), sudden cardiac death (HR=1.83), mortality (HR=2.61), heart failure (HR=3.31) and ischemic stroke (HR=3.34).
Source: Heart Rhythm - July 28, 2018 Category: Cardiology Authors: Ting-Yung Chang, Chin-Yu Lin, Shih-Ann Chen Source Type: research
EP News: Allied Professionals
Using data on patients in the United States Renal Data System (USRDS), Siontis et al (Circulation 2018; https://doi.org/10.1161/CIRCULATIONAHA.118.035418 [Epub ahead of print], PMID 29954737) sought to assess patterns of apixaban use and outcomes related to use of anticoagulants in patients with end-stage renal disease (ESRD) and atrial fibrillation (AF). As background, patient s with ESRD have both higher risk of bleeding and higher risk of stroke with AF. The Food and Drug Administration has approved updated labeling for the use of apixaban in patients with ESRD on the basis of a small pharmacokinetic study.
Source: Heart Rhythm - July 26, 2018 Category: Cardiology Authors: Erica S. Zado Tags: EP News Source Type: research
Silent cerebral embolism in cryoballoon ablation of atrial fibrillation: When details matter
Although the clinically manifest stroke rate related to pulmonary vein isolation (PVI) is rare and currently
Source: Heart Rhythm - July 23, 2018 Category: Cardiology Authors: Jacopo Marazzato, Roberto De Ponti Tags: Editorial Commentary Source Type: research
Silent cerebral embolism in cryoballoon ablation of atrial fibrillation: when details matter.
Although the clinically manifest stroke rate related to pulmonary vein isolation (PVI) is rare and currently
Source: Heart Rhythm - July 23, 2018 Category: Cardiology Authors: Jacopo Marazzato, Roberto De Ponti Source Type: research
Feasibility of Left Atrial Appendage Device Closure Following Chronically Failed Surgical Ligation
Incomplete surgical left atrial appendage occlusion (S-LAAO) with a narrow neck has been shown to predict an increased rate of embolic stroke. Patients with a previously attempted S-LAAO were systematically excluded from all clinical trials of LAA closure devices.
Source: Heart Rhythm - July 15, 2018 Category: Cardiology Authors: Christopher R. Ellis, Mohamed Metawee, Robert N. Piana, Jeremy M. Bennett, Mias Pretorius, Robert J. Deegan Source Type: research
Device-Guided Anticoagulation in Atrial Fibrillation: Not yet ready for prime time
Atrial fibrillation (AF), the most common sustained arrhythmia encountered in clinical practice, is associated with a three- to five-fold increased risk of stroke (accounting for>20% of all strokes).1 Independent of age and other risk factors, AF-associated strokes are relatively more severe, causing greater resource utilization, long-term disability, and mortality compared to non-AF stroke. Oral anticoagulants (OACs) are paramount in preventing AF-associated stroke and systemic thromboembolism.
Source: Heart Rhythm - July 10, 2018 Category: Cardiology Authors: Christopher C. Cheung, Jason G. Andrade Source Type: research
Screening for Atrial Fibrillation using Smartphone-based Technology and Layperson Volunteers: High-Tech Meets Community Participatory Research for the Best of Both Worlds
Atrial fibrillation (AF), usually asymptomatic and not previously-diagnosed, increases risk of stroke by five times1 and accounts for 15-25% of strokes. 2 Asymptomatic AF is estimated to affect 600,000 Americans, with an estimated cost of 3 billion dollars per year.3 Just because we can identify a risk factor does not mean screening for it will save lives. AF, however, meets most criteria laid out in the World Health Organization ’s manifesto on screening, “Principles and Practice of Screening for Disease”.
Source: Heart Rhythm - July 4, 2018 Category: Cardiology Authors: Rachel Lampert Source Type: research
Seasonal variation in the risk of ischemic stroke in patients with atrial fibrillation: A nationwide cohort study
Several cardiovascular diseases exhibit seasonal variations, but data about cold temperature and risk of ischemic stroke in patients with atrial fibrillation (AF) are limited.
Source: Heart Rhythm - July 2, 2018 Category: Cardiology Authors: Jo-Nan Liao, Tze-Fan Chao, Chia-Jen Liu, Su-Jung Chen, Chung-Lieh Hung, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Ta-Chuan Tuan, Fa-Po Chung, Tzeng-Ji Chen, Gregory Y.H. Lip, Shih-Ann Chen Source Type: research
EP News: Allied Professionals
Using data from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, Lopes et al (J Am Coll Cardiol 2018;71:1063, PMID 29519345) sought to determine the effect of digoxin on mortality in patients with atrial fibrillation (AF). ARISTOTLE is a pivotal trial involving ∼18,000 patients with AF and at least 1 risk factor for stroke with randomization to apixaban or warfarin. T he present study is a post hoc analysis of those patients who were on digoxin at baseline as compared with those not on digoxin as well as an analysis of patients taking digoxin during the cour...
Source: Heart Rhythm - April 27, 2018 Category: Cardiology Authors: Erica S. Zado Source Type: research
Is A Little Atrial Fibrillation Still Too Much?
Atrial fibrillation (AF) is most often viewed as a dichotomous variable, one that is either entirely present or absent. Guidelines support this perspective by recommending anticoagulation based on underlying stroke risk without regard to AF “type”, duration, or burden.1 The use of cardiac monitoring, however, has allowed us to quantify AF and associate outcomes with various arrhythmia characteristics.2, 3 These types of studies have raised legitimate doubts as to whether the 30 second threshold used to define AF is associated with meaningful consequences and have created equipoise for sub-clinical AF episodes lasting minutes to hours.
Source: Heart Rhythm - February 24, 2018 Category: Cardiology Authors: Rod Passman Source Type: research
Is a little atrial fibrillation still too much?
Atrial fibrillation (AF) is most often viewed as a dichotomous variable, one that is either entirely present or absent. Guidelines support this perspective by recommending anticoagulation based on underlying stroke risk without regard to AF “type,” duration, or burden.1 The use of cardiac monitoring, however, has allowed us to quantify AF and associate outcomes with various arrhythmia characteristics.2,3 These types of studies have raised legitimate doubts as to whether the 30-second threshold used to define AF is associated with m eaningful consequences and have created equipoise for subclinical AF episodes lasting minutes to hours.
Source: Heart Rhythm - February 24, 2018 Category: Cardiology Authors: Rod Passman Tags: Editorial Commentary Source Type: research
